Neurocrine Biosciences Reports Strong Q4 & FY25 Results, Provides Solid 2026 Guidance, and Advances Pipeline
Summary
Neurocrine Biosciences announced strong Q4 and full-year 2025 financial results, exceeding prior year performance with double-digit revenue growth, and provided positive 2026 guidance for INGREZZA sales while highlighting significant pipeline advancements.
Key Events
-
Strong Q4 and Full-Year 2025 Financial Performance
Total net product sales for Q4 2025 reached $798.3 million, a 29% increase year-over-year, and full-year 2025 sales were $2.83 billion, up 22% from 2024. GAAP diluted EPS for Q4 2025 was $1.48, compared to $1.00 in Q4 2024.
-
INGREZZA and CRENESSITY Drive Sales Growth
INGREZZA net product sales grew 7% in Q4 2025 to $657.5 million and 9% for the full year to $2.51 billion. CRENESSITY, a newer product, demonstrated substantial growth with Q4 2025 net product sales of $135.3 million and full-year sales of $301.2 million.
-
Solid 2026 INGREZZA Sales Guidance
The company provided 2026 net product sales guidance for INGREZZA in the range of $2.7 billion to $2.8 billion, indicating continued growth for its key product.
-
Robust Pipeline Advancements
Neurocrine highlighted progress in its R&D engine, including Phase 3 programs for osavampator in major depressive disorder and direclidine in schizophrenia, and initiated a Phase 2 study for NBI-1065890, a next-generation VMAT2 inhibitor for tardive dyskinesia.
Analysis
Neurocrine Biosciences delivered robust financial results for both the fourth quarter and full fiscal year 2025, driven by significant growth in total net product sales and a successful launch of CRENESSITY. The company's flagship product, INGREZZA, also showed solid growth, despite strategic formulary access investments. The provided 2026 guidance for INGREZZA indicates continued revenue expansion. Furthermore, the company highlighted a strong and expanding pipeline, including multiple Phase 3 programs and new clinical study initiations, underscoring its commitment to diversification and long-term value creation. The substantial increase in cash reserves further strengthens its financial position to support ongoing R&D and commercialization efforts.
At the time of this filing, NBIX was trading at $137.44 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $13.7B. The 52-week trading range was $84.23 to $160.18. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.